In this randomized trial, among patients with idiopathic pulmonary fibrosis (IPF), nerandomilast slowed the decline in the ...

BACKGROUND: Direct reprogramming of fibroblasts to cardiomyocytes is a potentially curative strategy for ischemic heart ...

Nine new homosecoiridoid alkaloids, named lonijaposides O–W (1–9), along with 19 known compounds, were isolated from an aqueous extract of the flower buds of Lonicera japonica. Their structures and ...

Numerous studies and the modern ‐omics approaches have highlighted TGF‐β involvement in the modulation of multiple signaling pathways, important in activating the myofibroblast. 44, 90, 91 Novel use ...

Objective In the liver, the transcription factor, Kruppel-like factor 2 (KLF2), is induced early during progression of cirrhosis to lessen the development of vascular dysfunction; nevertheless, its ...

According to data from the Health Insurance Review and Assessment Service in 2023, there are an estimated 15,000 patients ...

The global progressive pulmonary fibrosis (PPF) treatment market is projected to be valued at USD 4,044.6 Million in 2025 and is expected to reach USD 8,182.4 Million by 2035, registering a CAGR of 7.

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Recent studies, including one from Tufts University, suggest that moderate coffee consumption, about 1-2 cups daily, may lower mortality risk by 14%, ...

Gyre Therapeutics has a unique business model for evaluating and commercializing drugs in China. Find out why GYRE stock is a ...

Combined antifibrotic and pulmonary vasodilator therapy may help transplant-free survival in patients with PH associated with pulmonary fibrosis.

Liver fibrosis (LF) is a pathological condition that, if not controlled, can progress into liver sclerosis and malignant tumors. Ferroptosis has been comprehensively studied and found to improve LF by ...